- At the European Cancer Congress, Ariad Pharmaceuticals (ARIA) gives an update on the Phase 1/2 trial of AP26113.
- According to the company, the tyrosine kinase inhibitor demonstrated "robust anti-tumor activity" in patients with TKI-naïve and crizotinib-resistant ALK+ non-small cell lung cancer.
- Additionally, it appears the drug is active in patients with brain metastases. (PR)
Ariad says AP26113 continues to show promise in advanced NSCLC
From other sites
at CNBC.com (Jan 16, 2015)
at CNBC.com (Jan 14, 2015)
Video at CNBC.com (Jan 13, 2015)
at CNBC.com (Jan 13, 2015)
at CNBC.com (Jan 9, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs